RecruitingPhase 3NCT07220772
A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults
Studying Syndromic obesity
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Regeneron Pharmaceuticals
- Principal Investigator
- Clinical Trial ManagementRegeneron Pharmaceuticals
- Intervention
- Mibavademab(drug)
- Enrollment
- 4 target
- Eligibility
- 2 years · All sexes
- Timeline
- 2026 – 2028
Study locations (1)
- ULM University Medical Centre, Ulm, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07220772 on ClinicalTrials.gov